CN106822239A - It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof - Google Patents
It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof Download PDFInfo
- Publication number
- CN106822239A CN106822239A CN201611172225.0A CN201611172225A CN106822239A CN 106822239 A CN106822239 A CN 106822239A CN 201611172225 A CN201611172225 A CN 201611172225A CN 106822239 A CN106822239 A CN 106822239A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese
- infection
- respiratory tract
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/264—Aristolochia (Dutchman's pipe)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of Chinese and western medicinal composition for treating the infection of the upper respiratory tract, the Chinese and western medicinal composition of the treatment infection of the upper respiratory tract is according to the primary raw material of weight portion：20 30 parts of trilobatin, 10 15 parts of aspirin, 5 13 parts of β acetoxyl group isovaleryls Alkannin, 8 14 parts of cefathiamidine, 27 35 parts of Chinese ephedra, 68 parts of root of large-flowered skullcap B, 49 parts of birthwort E, 16 19 parts of peppermint, 26 parts of donaxine, loose 26 parts of ester alcohol diglucoside.Medicine of the present invention is strictly selected material composition according to the understanding mechanism of the infection of the upper respiratory tract, so as to reach the purpose of comprehensive rehabilitation, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of Chinese and western medicinal composition for treating the infection of the upper respiratory tract.
Background technology
The infection of the upper respiratory tract refers to the general name from nasal cavity to the acute inflammation between throat, is most common infectious disease
Disease.Caused by virus more, after bacterium infection often infects secondary to virus.The sick four seasons, any age can fall ill, by containing
The virulent spittle, droplet, or through pollute apparatus propagated.Motherland's medical science to infectious disease, particularly to respiratory tract infection
The understanding of disease and preventing and treating are with a long history.Early in before more than 2,000 years, Han dynasty Zhang Zhongjing just has related discussion to go out preventing and treating side's medicine side by side.Mesh
Although the Chinese patent drug species of preceding in the market treatment infection of the upper respiratory tract disease is various, presence such as dosage is big, the term of validity
The inapparent problem of short, curative effect.
Therefore, it is badly in need of a kind of suitable good effect of research and development, speed is fast, price is low, the Chinese and western medicinal composition that has no toxic side effect.
The content of the invention
It is an object of the invention to provide a kind of Chinese and western medicinal composition for treating the infection of the upper respiratory tract, to solve above-mentioned background
The problem proposed in technology.
To achieve the above object, the present invention provides following technical scheme：
A kind of Chinese and western medicinal composition for treating the infection of the upper respiratory tract, be according to the primary raw material of weight portion：Trilobatin 20-30
Part, aspirin 10-15 part, β -5-13 parts of acetoxyl group isovaleryl Alkannin, cefathiamidine 8-14 parts, Chinese ephedra 27-35 parts, Huang
6-8 parts of a kind of reed mentioned in ancient books B, 4-9 parts of birthwort E, peppermint 16-19 parts, donaxine 2-6 parts, loose 2-6 parts of ester alcohol diglucoside.
As further scheme of the invention：The Chinese and western medicinal composition of the treatment infection of the upper respiratory tract, according to weight portion
Primary raw material be：Trilobatin 24-27 parts, aspirin 12-15 parts, β -7-12 parts of acetoxyl group isovaleryl Alkannin, cephalo
10-12 parts of sulphur amidine, Chinese ephedra 29-31 parts, 6-8 parts of root of large-flowered skullcap B, 4-9 parts of birthwort E, peppermint 16-19 parts, donaxine 2-6 parts, pine
2-6 parts of ester alcohol diglucoside.
As further scheme of the invention：The Chinese and western medicinal composition of the treatment infection of the upper respiratory tract, according to weight portion
Primary raw material be：26 parts of trilobatin, 14 parts of aspirin, β -10 parts of acetoxyl group isovaleryl Alkannin, 11 parts of cefathiamidine,
30 parts of Chinese ephedra, 7 parts of root of large-flowered skullcap B, 7 parts of birthwort E, 18 parts of peppermint, 4 parts of donaxine, loose 4 parts of ester alcohol diglucoside.
A kind of preparation method of the Chinese and western medicinal composition for treating the infection of the upper respiratory tract, concretely comprises the following steps：
First, in pharmaceutical grade clean area, trilobatin, aspirin, β-acetoxyl group isoamyl are weighed by above-mentioned metering ratio
Acyl Alkannin, cefathiamidine, Chinese ephedra, root of large-flowered skullcap B, birthwort E, peppermint, donaxine, loose ester alcohol diglucoside, sieving, machinery are mixed
Addition ultra-pure water after even, places in pharmacy mixer, mixes 4-8min, controls RSD≤5%, compressing tablet and low temperature drying after mixing,
At 4-8 DEG C, packaging obtains final product the Chinese and western medicinal composition of the treatment infection of the upper respiratory tract to temperature control.
As further scheme of the invention：Mix 6min in specific steps.
Compared with prior art, the beneficial effects of the invention are as follows：
Medicine of the present invention is strictly selected material composition according to the understanding mechanism of the infection of the upper respiratory tract, complete so as to reach
The purpose of face rehabilitation, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of Chinese and western medicinal composition for treating the infection of the upper respiratory tract, be according to the primary raw material of weight portion：20 parts of trilobatin,
10 parts of aspirin, β -5 parts of acetoxyl group isovaleryl Alkannin, 8 parts of cefathiamidine, 27 parts of Chinese ephedra, 6 parts of root of large-flowered skullcap B, birthwort E
4 parts, 16 parts of peppermint, 2 parts of donaxine, loose 2 parts of ester alcohol diglucoside.
A kind of preparation method of the Chinese and western medicinal composition for treating the infection of the upper respiratory tract, concretely comprises the following steps：
First, in pharmaceutical grade clean area, trilobatin, aspirin, β-acetoxyl group isoamyl are weighed by above-mentioned metering ratio
Acyl Alkannin, cefathiamidine, Chinese ephedra, root of large-flowered skullcap B, birthwort E, peppermint, donaxine, loose ester alcohol diglucoside, sieving, machinery are mixed
Addition ultra-pure water after even, places in pharmacy mixer, mixes 4min, controls RSD≤5%, compressing tablet and low temperature drying after mixing, temperature
At 4 DEG C, packaging obtains final product the Chinese and western medicinal composition of the treatment infection of the upper respiratory tract for degree control.
Embodiment 2
A kind of Chinese and western medicinal composition for treating the infection of the upper respiratory tract, be according to the primary raw material of weight portion：24 parts of trilobatin,
12 parts of aspirin, β -7 parts of acetoxyl group isovaleryl Alkannin, 10 parts of cefathiamidine, 29 parts of Chinese ephedra, 6 parts of root of large-flowered skullcap B, birthwort
4 parts of E, 16 parts of peppermint, 2 parts of donaxine, loose 2 parts of ester alcohol diglucoside.
A kind of preparation method of the Chinese and western medicinal composition for treating the infection of the upper respiratory tract, concretely comprises the following steps：
First, in pharmaceutical grade clean area, trilobatin, aspirin, β-acetoxyl group isoamyl are weighed by above-mentioned metering ratio
Acyl Alkannin, cefathiamidine, Chinese ephedra, root of large-flowered skullcap B, birthwort E, peppermint, donaxine, loose ester alcohol diglucoside, sieving, machinery are mixed
Addition ultra-pure water after even, places in pharmacy mixer, mixes 4min, controls RSD≤5%, compressing tablet and low temperature drying after mixing, temperature
At 4 DEG C, packaging obtains final product the Chinese and western medicinal composition of the treatment infection of the upper respiratory tract for degree control.
Embodiment 3
A kind of Chinese and western medicinal composition for treating the infection of the upper respiratory tract, be according to the primary raw material of weight portion：26 parts of trilobatin,
14 parts of aspirin, β -10 parts of acetoxyl group isovaleryl Alkannin, 11 parts of cefathiamidine, 30 parts of Chinese ephedra, 7 parts of root of large-flowered skullcap B, horse pocket
7 parts of bell E, 18 parts of peppermint, 4 parts of donaxine, loose 4 parts of ester alcohol diglucoside.
A kind of preparation method of the Chinese and western medicinal composition for treating the infection of the upper respiratory tract, concretely comprises the following steps：
First, in pharmaceutical grade clean area, trilobatin, aspirin, β-acetoxyl group isoamyl are weighed by above-mentioned metering ratio
Acyl Alkannin, cefathiamidine, Chinese ephedra, root of large-flowered skullcap B, birthwort E, peppermint, donaxine, loose ester alcohol diglucoside, sieving, machinery are mixed
Addition ultra-pure water after even, places in pharmacy mixer, mixes 6min, controls RSD≤5%, compressing tablet and low temperature drying after mixing, temperature
At 6 DEG C, packaging obtains final product the Chinese and western medicinal composition of the treatment infection of the upper respiratory tract for degree control.
Embodiment 4
A kind of Chinese and western medicinal composition for treating the infection of the upper respiratory tract, be according to the primary raw material of weight portion：27 parts of trilobatin,
15 parts of aspirin, β -12 parts of acetoxyl group isovaleryl Alkannin, 12 parts of cefathiamidine, 31 parts of Chinese ephedra, 8 parts of root of large-flowered skullcap B, horse pocket
9 parts of bell E, 19 parts of peppermint, 6 parts of donaxine, loose 6 parts of ester alcohol diglucoside.
A kind of preparation method of the Chinese and western medicinal composition for treating the infection of the upper respiratory tract, concretely comprises the following steps：
First, in pharmaceutical grade clean area, trilobatin, aspirin, β-acetoxyl group isoamyl are weighed by above-mentioned metering ratio
Acyl Alkannin, cefathiamidine, Chinese ephedra, root of large-flowered skullcap B, birthwort E, peppermint, donaxine, loose ester alcohol diglucoside, sieving, machinery are mixed
Addition ultra-pure water after even, places in pharmacy mixer, mixes 8min, controls RSD≤5%, compressing tablet and low temperature drying after mixing, temperature
At 8 DEG C, packaging obtains final product the Chinese and western medicinal composition of the treatment infection of the upper respiratory tract for degree control.
Embodiment 5
A kind of Chinese and western medicinal composition for treating the infection of the upper respiratory tract, be according to the primary raw material of weight portion：30 parts of trilobatin,
15 parts of aspirin, β -13 parts of acetoxyl group isovaleryl Alkannin, 14 parts of cefathiamidine, 35 parts of Chinese ephedra, 8 parts of root of large-flowered skullcap B, horse pocket
9 parts of bell E, 19 parts of peppermint, 6 parts of donaxine, loose 6 parts of ester alcohol diglucoside.
A kind of preparation method of the Chinese and western medicinal composition for treating the infection of the upper respiratory tract, concretely comprises the following steps：
First, in pharmaceutical grade clean area, trilobatin, aspirin, β-acetoxyl group isoamyl are weighed by above-mentioned metering ratio
Acyl Alkannin, cefathiamidine, Chinese ephedra, root of large-flowered skullcap B, birthwort E, peppermint, donaxine, loose ester alcohol diglucoside, sieving, machinery are mixed
Addition ultra-pure water after even, places in pharmacy mixer, mixes 8min, controls RSD≤5%, compressing tablet and low temperature drying after mixing, temperature
At 8 DEG C, packaging obtains final product the Chinese and western medicinal composition of the treatment infection of the upper respiratory tract for degree control.
Pharmacology test
1st, acute toxicity test
It is experiment with Chinese and western medicinal composition obtained in the embodiment of the present invention 3, it is continuous in 24h using gastric infusion mode
Administration 3 times, per minor tick 6h, is administered 240mg/kg doses every time, and daily accumulation medicine total amount reaches 720mg medicines/kg, equivalent to
60 times of people's quantity.After administration in 7d, mouse activity, feed, excretion are normal, well-grown, hair color light, and its is average
Body weight increases with the extension of experimental period.Every mouse of post mortem at 8d, visually observe the heart, liver, spleen, lung, kidney,
Brain, thymus gland, stomach, intestines etc. do not find color and paramophia, fail to measure median lethal dose (LD50).Result shows：This hair
Bright Chinese and western medicinal composition is without acute toxic reaction.
2nd, long term toxicity test
It is experiment with Chinese and western medicinal composition obtained in the embodiment of the present invention 3, using gastric infusion mode, by Chinese and Western of the present invention
Drug composition is divided into low dosage, middle dosage, three groups of high dose, the drug dose of each group is respectively 120,240,360mg medicines/
Kg/d, 10,20,30 times equivalent to clinical dosage.After gastric infusion 24 weeks, general status, blood of the medicine of the present invention to animal
, without obvious influence, Systematic anatomy, organ coefficient and histopathological examination do not find yet for liquid index, blood parameters
Abnormal pathologic changes.It is discontinued 2 weeks and also has no substantially change.Result shows：Chinese and western medicinal composition of the present invention is in long term toxicity test
In, do not find overt toxicity reaction and delayed toxicity reaction.It can be seen that, Chinese and western medicinal composition non-toxic reaction of the present invention is long-term to use
Medicine is safe and reliable.
3rd, clinical test
Accept totally 200 infection of the upper respiratory tract patients for medical treatment, wherein, male 100, women 100；Give the embodiment of the present invention
3 Chinese and western medicinal compositions for preparing, according to 12mg/kg/ days, 3 days as one therapeutic course (three courses for the treatment of of treatment) carried out symptom follow-up record；
Clinical efficacy criterion is to cure：Cardinal symptom, sign are wholly or substantially alleviated, and objective indicator recovers normal；It is effective：It is main
Symptom, sign is wanted to be relieved, objective indicator is close to normally；Effectively：Cardinal symptom, sign take a turn for the better, and objective indicator makes moderate progress；
It is invalid：Cardinal symptom, sign are unchanged, and objective indicator change substantially or is not aggravated.
Treatment results：200 patients, 144 recoveries from illness, 27 are effective, and 22 are effectively, 7 invalid, total effective rates
96.5%.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires to be limited rather than described above, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each implementation method is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should
Specification an as entirety, the technical scheme in each embodiment can also be formed into those skilled in the art through appropriately combined
May be appreciated other embodiment.
Claims (5)
1. a kind of Chinese and western medicinal composition for treating the infection of the upper respiratory tract, it is characterised in that the primary raw material according to weight portion is：Three
20-30 parts of leaf glucoside, aspirin 10-15 parts, β -5-13 parts of acetoxyl group isovaleryl Alkannin, cefathiamidine 8-14 parts, Chinese ephedra
27-35 parts, 6-8 parts of root of large-flowered skullcap B, 4-9 parts of birthwort E, peppermint 16-19 parts, donaxine 2-6 parts, loose ester alcohol diglucoside 2-6
Part.
2. it is according to claim 1 treatment the infection of the upper respiratory tract Chinese and western medicinal composition, it is characterised in that in the treatment
The Chinese and western medicinal composition of respiratory tract infection, be according to the primary raw material of weight portion：Trilobatin 24-27 parts, aspirin 12-15
Part, β -7-12 parts of acetoxyl group isovaleryl Alkannin, cefathiamidine 10-12 parts, Chinese ephedra 29-31 parts, 6-8 parts of root of large-flowered skullcap B, horse pocket
4-9 parts of bell E, peppermint 16-19 parts, donaxine 2-6 parts, loose 2-6 parts of ester alcohol diglucoside.
3. it is according to claim 1 and 2 treatment the infection of the upper respiratory tract Chinese and western medicinal composition, it is characterised in that it is described to control
The Chinese and western medicinal composition of the infection of the upper respiratory tract is treated, is according to the primary raw material of weight portion：26 parts of trilobatin, 14 parts of aspirin,
β -10 parts of acetoxyl group isovaleryl Alkannin, 11 parts of cefathiamidine, 30 parts of Chinese ephedra, 7 parts of root of large-flowered skullcap B, 7 parts of birthwort E, peppermint 18
Part, 4 parts of donaxine, loose 4 parts of ester alcohol diglucoside.
4. the preparation method of the Chinese and western medicinal composition of a kind for the treatment of infection of the upper respiratory tract as described in claim 1-3 is any, its
It is characterised by, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh trilobatin, aspirin, β-acetoxyl group isovaleryl Ah
Block peaceful, cefathiamidine, Chinese ephedra, root of large-flowered skullcap B, birthwort E, peppermint, donaxine, loose ester alcohol diglucoside, sieving, after machinery mixing
Addition ultra-pure water, places in pharmacy mixer, mixes 4-8min, controls RSD≤5%, compressing tablet and low temperature drying, temperature after mixing
At 4-8 DEG C, packaging obtains final product the Chinese and western medicinal composition of the treatment infection of the upper respiratory tract for control.
5. it is according to claim 4 treatment the infection of the upper respiratory tract Chinese and western medicinal composition preparation method, it is characterised in that
Mix 6min in specific steps.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611172225.0A CN106822239A (en) | 2016-12-17 | 2016-12-17 | It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611172225.0A CN106822239A (en) | 2016-12-17 | 2016-12-17 | It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106822239A true CN106822239A (en) | 2017-06-13 |
Family
ID=59140035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611172225.0A Withdrawn CN106822239A (en) | 2016-12-17 | 2016-12-17 | It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106822239A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108379278A (en) * | 2018-05-08 | 2018-08-10 | 南方医科大学 | Application of the trifloroside in preparing anti HIV-1 virus infection medicine |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634479A (en) * | 2004-03-12 | 2005-07-06 | 诺氏制药（吉林）有限公司 | Medicine composition for treating cold and upper respiratory tract infection, preparation method and purpose thereof |
| CN102716223A (en) * | 2012-06-27 | 2012-10-10 | 巫军 | Chinese medicinal composition for treating upper respiratory tract infection and preparation method thereof |
| CN104524585A (en) * | 2014-12-08 | 2015-04-22 | 悦康药业集团有限公司 | Cefathiamidine composition |
-
2016
- 2016-12-17 CN CN201611172225.0A patent/CN106822239A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634479A (en) * | 2004-03-12 | 2005-07-06 | 诺氏制药（吉林）有限公司 | Medicine composition for treating cold and upper respiratory tract infection, preparation method and purpose thereof |
| CN102716223A (en) * | 2012-06-27 | 2012-10-10 | 巫军 | Chinese medicinal composition for treating upper respiratory tract infection and preparation method thereof |
| CN104524585A (en) * | 2014-12-08 | 2015-04-22 | 悦康药业集团有限公司 | Cefathiamidine composition |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108379278A (en) * | 2018-05-08 | 2018-08-10 | 南方医科大学 | Application of the trifloroside in preparing anti HIV-1 virus infection medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106822239A (en) | It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof | |
| CN104546928A (en) | Traditional Chinese medicinal composition for treating infantile diaper rash and preparation method of traditional Chinese medicinal composition | |
| CN104083508B (en) | Preparation method of traditional Chinese medicine preparation for preventing and treating respiratory disease caused by chicken airbag inflammation | |
| CN106727615A (en) | A kind of Western medicine compound for treating the infection of the upper respiratory tract | |
| CN106806376A (en) | The pharmaceutical composition of paracetamol and glycyrrhizic acid or its salt or derivatives thereof | |
| CN106581274A (en) | Chinese and western medicine composite for treating amygdalitis and preparing method thereof | |
| CN106511440A (en) | Compound Chinese and Western medicine composition for treating chronic dysentery and preparation method thereof | |
| CN106727642A (en) | A kind of children's antipyretic | |
| CN106620642A (en) | Western medicine composition for treating hyperglycemia | |
| CN103751355B (en) | A kind of have the pharmaceutical composition promoting leukocyte effect | |
| CN106727907A (en) | A kind of Chinese and Western medicine combination for treating viral pneumonia and preparation method thereof | |
| CN106727647A (en) | A kind of medicine for treating fatty liver | |
| CN106581031A (en) | Compound Western medicine for treating pertussis | |
| CN106668600A (en) | Composite preparation for treating chronic glomerulitis | |
| CN1164283C (en) | Pulmonotis treating Chinese medicine powder | |
| CN106581024A (en) | Western medicine composition for treating hyperlipidemia | |
| CN106727508A (en) | A kind of combination drug for treating chronic dysentery | |
| CN106728768A (en) | It is a kind of to treat Chinese and western medicinal composition of hyperglycaemia and preparation method thereof | |
| CN106581025A (en) | Composite western medicine for treating chronic dysentery | |
| CN102908493A (en) | Emergency drug for treating hydrophobia | |
| CN106728049A (en) | It is a kind of to treat scorching Chinese and Western medicine composite preparation of chronic glomerulus and preparation method thereof | |
| CN106727786A (en) | A kind of antipyretic of children's Integrated TCM and preparation method thereof | |
| CN106692457A (en) | Medicine for treating viral pneumonia | |
| CN107551105A (en) | One kind treats mouth week eczema Chinese medicine | |
| CN106619650A (en) | Compound preparation for treating chronic glomerulitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170613 |